Neoleukin Therapeutics, Inc. stock is down -4.91% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November.
Neoleukin Therapeutics, Inc. develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.